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Abstract: Much of our knowledge regarding cancer immunotherapy has been derived from 
sarcoma models. However, translation of preclinical findings to bedside success has been 
limited in this disease, though several intriguing clinical studies hint at the potential 
efficacy of this treatment modality. The rarity and heterogeneity of tumors of mesenchymal 
origin continues to be a challenge from a therapeutic standpoint. Nonetheless, sarcomas 
remain attractive targets for immunotherapy, as they can be characterized by specific 
epitopes, either from their mesenchymal origins or specific alterations in gene products.  
To date, standard vaccine trials have proven disappointing, likely due to mechanisms  
by which tumors equilibrate with and ultimately escape immune surveillance. More 
sophisticated approaches will likely require multimodal techniques, both by enhancing 
immunity, but also geared towards overcoming innate mechanisms of immunosuppression 
that favor tumorigenesis.  
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1. Introduction 
Bone and soft tissue sarcomas compromise a rare and heterogeneous array of tumors derived from 
mesenchymal origins. Clinical behavior varies between subtypes, with a wide range of natural history, 
progression and susceptibility to therapy. The aggressive use of multimodal therapy has improved 
outcomes in a subset of sarcoma, but disease presenting with metastatic spread usually portends an 
extremely poor outcome. Immunotherapy targeted against sarcoma may open a new front in the battle 
against these malignancies, with utility in the neoadjuvant, adjuvant and metastatic settings.  
2. Historical Precedents 
Immune protection against tumors is a concept over a century old, waxing and waning in popularity 
over the decades. Importantly, one of the first germane observations relevant to this theory was 
predicated on an observation of a sarcoma patient. In 1891, Coley [1] noted a patient with small cell 
sarcoma cleared of disease following an erysipelas infection, proposing an anti-infectious mechanism 
with antitumor effects. He tested his hypothesis by inducing infections and later injecting  
heat-inactivated bacteria to stimulate an immune response with dramatic effects in some sarcoma 
patients [2]. In 1909, Paul Erlich [3] had expanded on earlier discussions regarding immunity [4] to 
encompass cancer as a target. Coley’s results were difficult to replicate, and while the idea lost credence 
for a time, it was revived with mid-20th century theories of “tumor surveillance” by Thomas [5] and 
Burnet [6,7]. Again initially discounted, this paradigm was eventually validated by a growing body of 
data, once again with sarcoma studies leading the way.  
3. Pre- and Early Clinical Sarcoma Studies Contribute to a General Immunosurveillance Model  
Following the observation that it was possible to induce immunity versus tumors previously felt to 
be non-immunogenic, provided the tumor cells were mutagenized with carcinogens [8], numerous 
subsequent studies using sarcoma mouse models extended our understanding of the immune system’s 
ability to reject tumor cells. Preclinical studies with syngeneic mice injected with fibrosarcoma cells 
engineered to be insensitive to IFNγ demonstrated increased tumorigenicity versus their IFNγ-sensitive 
counterparts, inferring a role for this molecule in tumor cell immunogenicity, recognition and 
elimination [9]. These observations were fleshed out by the same investigators using IFNγ receptor 
knockout mice, [10] which were found to be more susceptible to sarcoma formation. Concurrent 
experiments noted perforin-deficient mice also demonstrated susceptibility to induced sarcomas [11]. 
With perforin’s role as a key component of cytotoxic T and NK cell lymphocyte-dependent killing, 
this line of evidence underscored the key role of these cells in rejecting induced malignancies. 
Similarly, mice deficient in genes necessary for NK, T and B cell antigen receptor rearrangement were 
also found to develop sarcomas at a significantly greater rate than control animals [12]. Together, these 
findings revived the notion of immune system management of primary tumor development, with a 
central role for cytotoxic T-lymphocytes (CTLs) and their cytokines.  
While these preclinical studies revitalized the idea of tumor immunosurveillance, evidence in the 
clinical realm kept in step with preclinical findings. A growing awareness of increased cancer 
susceptibility in immunocompromised patients was recognized, in both immunosuppressed transplant 
Cancers 2011, 3                
 
 
4141
patients [13] as well as those harboring congenital or acquired immunodeficiencies [14,15]. A wide 
variety of tumor types have been recognized in several epidemiological studies of such patients, 
including sarcoma [16,17]. HHV 8-related Kaposi sarcoma is a model for viremia-associated tumors in 
immunocompromised hosts, but those without a known viral etiology have also been noted.  
In addition, the finding of individuals with CTL infiltration of tumors harboring a more favorable 
prognosis has been similarly suggestive of the crucial role the immune system plays in combating 
tumorogenesis [18]. 
The combined preclinical and clinical studies provide the basis of the “cancer immunoediting” 
paradigm. Three key phases of the current model are described: elimination, equilibrium and  
escape [19]. In the elimination phase, the innate and adaptive elements of immune system recognize 
and destroy nascent tumor cells. Some tumor cells survive and are “sculpted” by the immune system in 
a selection process to reach a degree of equilibrium [12,20] whereby they may persist, but not 
progress. Finally, a subset of these equilibrated tumor cells escape immune management by disabling 
immune recognition, often co-opting the system for growth, invasion and angiogenesis [21-26]. 
Further investigation of these phases are instrumental in understanding how the immune system works 
against cancer, how it can be subverted by tumor cells, and ultimately in harvesting the power of 
immunity in the search for therapeutic alternatives.  
4. Vaccine Studies 
Despite preclinical precedents, sarcoma immunotherapy remains poorly characterized in humans. 
Many sarcoma subtypes harbor attractive targets for immune-mediated strategies due to the presence 
of specific epitopes, either based on cell of origin or alterations of gene products, leading to ongoing 
enthusiasm for this technique. Specifically, up to a fourth of sarcomas are characterized by reproducible 
genetic changes, potentially providing tumor-specific immune recognition sites. Unfortunately, 
meaningful responses to vaccination in solid tumors has been disappointing, with “modern” efforts in 
sarcoma dating back some 40 years [27]. Vaccines targeting whole cells, lysates, proteins, and peptides 
specific to sarcoma subtypes (especially translocation-specific epitopes) have been tested to little avail, 
although several clinical studies are ongoing in the hopes of a breakthrough (Table 1).  
The lack of efficacy seen by these sarcoma studies may partially be due to the lackluster response 
by T-cells responding to the vaccine. Often less than 1% of the CTLs with the desired T-cell receptor 
are detected in the peripheral circulation following vaccination trials, in contrast to the avid response 
of CTLs to viral epitopes (in the range of 20-50% or more). Attempts with costimulators such as 
saponin, KLH, or Freund’s adjuvant have not improved response markedly, nor has addition of other 
immune stimulants such as GMCSF or IL-2. However, improving the yield of active CTLs in vivo is 
unlikely to be enough. Even in situations where as many as 30% of circulating CD8+ T-cells 
demonstrate anti-tumor reactivity, tumors can still thrive [28] The poor results of vaccine-only trials  
to date are likely due largely to the equilibrium and escape mechanisms sarcomas undergo in  
their evolution.  
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Table 1. Antigen epitopes with potential utility in sarcoma immunotherapy. Unless 
otherwise specified, references are described in [29]. It should be noted that some of the 
proposed epitopes are based on wide ranging of preclinical evidence.  
Antigens Sarcoma type Selected references 
Partial specificity:   
XAGE-1 Ewing  
LIP1 all sarcoma [30] 
GM2 all sarcoma [31,32] 
GD2, GD3 all sarcoma  
PRAME synovial, myxoid liposarcoma  
MAGE synovial,leiomyosarcoma, osteosarcoma [33] 
GAGE malignant fibrous histiocytoma  
WT-1 rhabdomyosarcoma  
FGR4 rhabdomyosarcoma  
ALK rhabdomyosarcoma [34,35] 
NY-ESO-1 synovial [36,37] 
4Ig-B7-H3 (8H9 target) all sarcoma [38] 
SSX2, SSX3 synovial  
Her2Neu osteosarcoma  
Sarcoma-specific fusion proteins:   
SSX fusions synovial [39] 
EWSR1 fusions Ewing family [40] 
FOXO1 fusions alveolar rhabdomyosarcoma [40] 
TLS-CHOP (FUS-DDIT3) myxoid liposarcoma  
Key to the equilibrium and escape mechanisms are other players in the panoply of immune 
mediators. Regulatory CD4+ CD25+ T cells (Tregs), first recognized in the early 1990s, are becoming 
better characterized, acting to suppress autoimmunity and playing a protective role for tumors [41]. 
Inhibitory cell surface components on infiltrating lymphocytes, such as PD-1 [42] and CTLA-4 [43] 
have been determined, with their presence resulting in CTL suppression. Also, CD11b+ and Gr-1+ 
myeloid-derived suppressor cells (MDSCs) [44] and tumor associated macrophages (TAMs) [44,45] 
play additional functions in immune suppression and tumor promotion, acting within the tumor 
microenvironment. As it has become increasingly clear that standard approaches of generating a 
response to a sarcoma-specific epitope are insufficient to mount a significant clinical tumor response, it 
appears likely further manipulations are necessary.  
Standard chemotherapeutics may be useful, as alkylating agents like cyclophosphamide or 
ifosfamide decrease Treg cells as part of their cytotoxic profile [46]. One may speculate that the 
efficacy of these agents in many sarcomas may be due, in part, to this action. Alkylators and other 
standard cytotoxics also destroy other suppressor cells such as MDSCs and TAMs, but have the 
undesired effect of indiscriminate destruction of desired CTLs. In order to circumvent the mediating 
influences of immune suppressors, newer agents targeting inhibitory cell surface components are being 
added to the arsenal of immunotherapeutics. The anti-CTLA4 agent ipilimumab is approved for 
melanoma immunotherapy and currently in clinical trials for patients with a variety of other solid 
tumors including various sarcoma subtypes (NCT00556881), although a trial with another anti-CTLA4 
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monoclonal antibody, MDX-010, in synovial sarcoma patients (NCT00140855) was closed due to poor 
accrual. Means to inhibit Tregs, MDSCs and TAMs are also being developed, acting by direct 
neutralization [47-50], or differentiation [51]. Human recombinant IL7 is a promising agent in this 
regard, as this cytokine appears to not only increase T-cell cycling and mass and subsequent T-cell 
receptor diversity, but concomitantly downregulates Treg activity [52,53]. 
5. T-Cell Approaches: Passive and Active 
In addition to the above approaches, complementary strategies for vaccine-based immunotherapy 
that have demonstrated encouraging results in melanoma (and, more recently, prostate cancer [54]) 
continue to hold promise in sarcoma. They include adoptive or “passive” immunotherapy, with 
administration of CTLs selected in vitro for high affinity to tumor antigens that have undergone ex vivo 
expansion, free from negative selection pressure present during thymic development [55]. An advantage 
of this method when combined with standard chemotherapy is that it addresses the indiscriminate 
cytotoxicity of chemo as is seen with alkylators described above. Prior studies have laid the foundation 
for this approach in sarcoma with interesting results, [56] and a recent adoptive immunotherapy study 
by Robbins et al [36] has demonstrated promise in synovial sarcoma. In this small study, patients with 
tumors expressing the NY-ESO-1 antigen (expressed in 80% of synovial sarcomas) were recruited, 
along with NY-ESO-1 positive melanoma patients. Subjects were treated with a lymphodepleting 
chemotherapy regimen of cyclophosphamide and fludarabine followed by infusion of genetically 
modified autologous T lymphocytes designed to recognize a specific NY-ESO-1 epitope. Four of the 
six sarcoma patients (all of whom had progressed through multiple chemotherapeutic regimens), 
achieved a PR lasting from 5 to 18 months; 5/11 melanoma patients demonstrated clinical benefit, 
including two CRs. It should be noted that such treatments are not entirely “passive”, as the 
endogenous immune system is significantly modified by not only the adoptive transfer of T cells, but 
by lymphodepleting conditioning and post infusion immunomodulators given as part of most protocols. 
Distinct from adoptive or “passive” techniques, “active” immunotherapy methodologies continue to 
garner attention. Clinical sarcoma investigators have long tried various schemes with immune 
activators and cytokine stimulators, some with intriguing results. The CCG/POG phase III  
intergroup trial 0133 enrolled 677 osteosarcoma patients from 1993-7, randomizing half the  
patients to arms where they received adjuvant chemotherapy with liposomal muramyl tripeptide 
phosphatidylethanolamine (L-MTP-PE) as a biological response modifier [57, 58]. L-MTP-PE was 
chosen for its utility as a monocyte/macrophage activator, with downstream activation of other 
components of the immune response. In the presence of this agent, risk of recurrence and death were 
decreased 25% and 30% respectively. Due to the 2 × 2 factorial design of the study, a potential 
interaction between L-MTP-PE and ifosfamide initially confounded the results. However, in followup 
analysis, a difference in disease-free survival (DFS) was noted, and although this result did not achieve 
significance, overall survival demonstrated a slight but significant improvement [59]. Unfortunately, 
for patients with metastatic disease, L-MTP-PE did not achieve a statistically significant improvement 
in outcome [60]. 
Dendritic cells (DCs) are distinct from other antigen-presenting cells in their ability to induce 
primary T-cell responses, and defined subsets of mature DCs may have direct antitumor activity as 
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well [61]. Conversely, immature DCs can induce either suppressive TReg cells or unresponsive  
T-cells tilting the balance towards equilibrium or escape. A more technically complex “active” 
immunotherapeutic process is ex vivo expansion and maturation of antigen-presenting DCs pulsed with 
antigen, reintroducing these cells to the host as a form of a DC vaccine. DC vaccines have achieved a 
measure of success in other solid tumors and remain an active area of research in sarcoma. Although 
several DC-based vaccines continue to elicit interest in early phase sarcoma trials, they have thus far 
not panned out [40,62], though a current trial NCT00923351 is in process, utilizing a more thoroughly 
developed protocol with a more sophisticated DC scheme.  
6. Immune Modulators and Targeting 
Interferon is another “active” immunotherapeutic, an adjuvant effector presumed to act by myriad 
pathways, including directing macrophages towards cytotoxic antigen presenting phenotypes [63], 
connecting the innate and adaptive cellular immunity by enhancing the expression of tumor-associated 
antigens, promoting dendritic cell maturation and antigen presentation and promoting clonal 
expansion, survival and memory differentiation of T lymphocytes, especially the Th1 subset participating 
in cell-mediated immunity. Interferon has been investigated in osteosarcoma, both preclinically and 
clinically,with intriguing results [64-67]. Interferon therapy may also demonstrate limited utility in 
other subsets of sarcoma, such as desmoid tumors, epithelioid hemangioendothelioma, giant cell tumor 
of the bone and gastrointestinal stromal tumor (GIST), although this effect is primarily based on 
descriptive reports or case series, and would still be considered highly investigational in these settings. 
However, A recent phase II trial combining targeted therapy with interferon cytokine stimulation in 
patients with GIST has demonstrated interesting results [68]. The design utilized the action of the 
tyrosine kinase inhibitor imatinib to cause apoptosis and necrosis in sensitive GIST cells, followed by 
immunomodulation by peginterferon α-2b to stimulate the adaptive cellular immunity program. The 
advantage of imatinib over standard cytotoxics in this situation is not only its far superior efficacy 
against GIST, but its presumed ability to act without major destruction of the machinery necessary for 
an active immune response; indeed, imatinib appears to have inherent immune-modulatory properties, 
particularly in GIST [69,70]. Although the study was small and primarily hypothesis-generating,  
a more durable treatment response was noted in all patients compared to genotype-specific  
historical controls.  
In yet another line of attack, immunotherapeutics may involve direct antibody recognition of 
sarcoma-specific epitopes, targeting the associated cells for destruction. Antibody-dependent  
cell-mediated toxicity approaches in sarcoma have yet to reach the success of the anti-CD20  
antibody rituximab against CD-20 positive hematological malignancies. However, lymphoma 
immunoradiotherapeutics such as Y-90 labelled ibritumomab tiuxetan and I-131 labelled tositumomab 
may someday have analogues that are applicable to sarcoma. This is being investigated with the 
monoclonal antibody 8H9, which targets the 4Ig-B7-H3 epitope expressed in a variety of 
neuroectodermal, epithelial, and mesenchymal tissue, with high specificity to sarcoma, glioma  
and neuroblastoma [38]. This antibody has been radiolabelled with I-131 with success in a mouse 
model of rhabdomyosarcoma [71] and is moving forward with Phase I trials in humans (MSKCC 
protocol 09-090). 
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7. Conclusions 
In the future, further immunomodulatory steps may be required for immunotherapy to achieve 
meaningful success against myriad sarcoma subtypes. T-lymphocytes, activated macrophages and 
monocytes, NK and mature dendritic cells and effector cytokines can be manipulated as described 
previously. Not only should attention be paid to enhancing immune elements, but also to defeating 
immunosuppressive elements to combat immune tolerization. Combined strategies could therefore also 
address such players as immature dendritic cells, MDSCs, co-opted TAMs and Treg cells and 
associated suppressor cytokines within the tumor microenvironment.  
Much as the current state of the art in sarcoma treatment relies on integrated multidisciplinary 
efforts, it is very likely that such a combinatorial process will be necessary to maximize the promise of 
immunotherapy in this realm. In the future, as in the present, ultimate success will likely require input 
from multiple specialties dedicated to sarcoma. Primary tumor surgical resection/debulking and/or 
metastectomy combined with preparative chemotherapy and/or radiotherapy may well complement the 
efficacy of immunotherapeutics. Sarcoma remains an attractive immune target despite previous 
disappointments and as the process is more clearly elucidated, this procedure, once honed, will likely 
become an invaluable weapon in our therapeutic arsenal against a challenging and many-faced 
malignancy.  
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